The pharmacological management of opioid dependence has evolved significantly with the introduction of long-acting, prolonged-release subcutaneous formulations. Across international healthcare jurisdictions spanning the United States, Canada, Brazil, Mexico, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, and Switzerland, clinicians frequently evaluate the therapeutic utility and safety profile of Buvidal (buprenorphine prolonged-release solution for injection). […]